Graham Boyd, Sarah Trumble, Lanae Erickson Hatalsky
11 April 2014
Despite a federal prohibition on marijuana possession, sale, and use, Colorado and Washington recently became the first states to enact laws legalizing the recreational use of this drug. Although the Obama Administration has taken steps to attempt to deal with this evolving situation, we believe the status quo is untenable and Congress must act to provide certainty and a framework for these states moving forward. This report explains the problem and offers a solution.
For forty years the Misuse of Drugs Act 1971 has formed the corner stone of drug policy in Britain. The emergence of new psychoactive substances (‘legal highs’) during the past fifteen years or so has challenged the drug control system. The arrival in 2012 of a new psychoactive substance on the market, on average, every six days raises questions about how best to protect young people from unknown and unsafe drugs. The Government is considering this challenge and we hope this Inquiry report will make a helpful contribution to their deliberations.
Beau Kilmer, Jonathan P. Caulkins, Rosalie Liccardo Pacula, Robert J. MacCoun, Peter H. Reuter
07 July 2010
To learn more about the possible outcomes of marijuana legalization in California, RAND researchers constructed a model based on a series of estimates of current consumption, current and future prices, how responsive use is to price changes, taxes levied and possibly evaded, and the aggregation of nonprice effects (such as a change in stigma).
Ernestien Jensema, Martin Jelsma, Tom Kramer, Nang Pann Ei Kham, Gloria Lai, Tripti Tandon
16 February 2015
The decision of the Myanmar Government to review drug laws is not only timely, but also offers a prospect to improve the drugs legislation and to ensure that the laws address drug-related problems in the country more effectively.
The three UN Drug Conventions of 1961, 1971 and 1988 currently impose a ‘one-size-fits-all’ prohibitionist approach to drug policy throughout the world. This new report explains in detail how the Conventions could be amended in order to give countries greater freedom to adopt drug policies better suited to their special needs.
This brief report outlines the links between cannabis prohibition in British Columbia (Canada) and the growth of organized crime and related violence in the province, and is the first report of a coalition of concerned citizens and experts known as Stop the Violence BC. The report also defines the public health concept “regulation” and seeks to set the stage for a much needed public conversation and action on the part of BC politicians.
The New Zealand Law Commission was asked to address the efficacy of the Misuse of Drugs Act in reducing the demand for, and supply of, drugs prohibited under the International Drug Conventions. The Commission has recommended the existing Act be repealed and replaced by a new Act administered by the Ministry of Health. Justice Hammond said the thrust of the proposed new Act is to facilitate a more effective interface between the criminal justice and health sectors: “We need to recognise that the abuse of drugs is both a health and a criminal public policy problem.”
On 11 July 2013, the New Zealand Parliament passed the Psychoactive Substances Act. The legislation enacted a new legal framework for the testing, manufacture, sale, and regulation of psychoactive products with the responsibility on manufacturers to prove a product 'low risk before it could be sold.' The expectation is that the adoption of new modern drug policies will ensure that the drugs people do take are safe, and that help can be accessed easily for those who need it. If the New Zealand approach is successful, other countries might follow lead, or even improve on what has been have done so far.
Understanding the consequences of drug legalisation versus prohibition is important for policy. Most recently this subject has gained much political attention not only globally, but specifically in the Netherlands. This study will provide a contribution to the legalisation debate based on a microeconomic analysis of the effects of illegal markets. The research question is how to design a coherent soft drugs policy framework that maximizes social welfare within the Netherlands that precludes most historical, sociological and political debates. In particular, attention is restricted to ‘soft drugs’ better known as cannabis derived products like hashish and marijuana.
Beau Kilmer, Kristy Kruithof, Mafalda Pardal, Jonathan P. Caulkins, Jennifer Rubin
14 December 2013
This RAND report provides an overview of the changes to laws and policies pertaining to cannabis in different countries. Several jurisdictions have reduced the penalties for possessing cannabis for personal use (and in some places even for home cultivation), while some jurisdictions have taken more dramatic steps and changed their laws and practices with respect to producing and distributing cannabis.
Robin Room, Peter Reuter (RAND), Wayne Hall, Benedikt Fischer, Simon Lenton, Amanda Fielding
01 September 2008
Despite cannabis being the most widely used illegal drug, and therefore the mainstay of the ‘war on drugs’, it has only ever held a relatively marginal position in international drug policy discussions. Amanda Fielding of the Beckley Foundation decided to convene a team of the world’s leading drug policy analysts to prepare an overview of the latest scientific evidence surrounding cannabis and the policies that control its use. The report of the Beckley Foundation's Global Cannabis Commission is aimed at bringing cannabis to the attention of policymakers and guide decision making.
Since first coming to public prominence at the end of 2009, legal highs have posed a major challenge to existing legal and legislative structures designed to deal with drugs. With the market in manufactured psychoactive substances like mephedrone moving faster than public policy can accommodate, this report asks whether the assumptions enshrined in the 40-year-old Misuse of Drugs Act (MDA) are still valid when applied 21st century drugs market.
No serious commentator doubts that cannabis is potentially damaging to the user. Like tobacco, it is typically smoked and thus shares the potential for lung disease. Like alcohol, it affects reaction times and may raise the risk of road accidents. Cannabis has also been associated with cognitive impairment, deterioration in education performance (van Ours and Williams 2008), and psychotic illness (Arsenault 2004). Moreover, cannabis is often – albeit contentiously – seen as a causal gateway to more serious drug use (Kandel 2002). The question is what to do about it?
The report reviews 20 years of data from US government funded surveillance systems on government drug control spending, cannabis seizures and cannabis arrests, in order to assess the impact of enforced cannabis prohibition on cannabis potency, price and availability. The report’s findings highlight the clear failure of cannabis prohibition efforts by showing that as the United States has dramatically scaled up drug law enforcement, cannabis potency has nevertheless increased, prices have dropped, and cannabis remains widely available.
Within the last decade the hitherto little known psychoactive substance of khat has emerged as a regional and international issue. In the Horn of Africa khat production has spurred an economic boom, but dramatic increases in consumption have raised public health concerns. Given the complexity of the topic spanning multiple academic disciplines and fields of professional practice, the need for a systematic overview is urgent.
Emily Crick, Heather J. Haase, David Bewley-Taylor
14 November 2013
In November 2012, voters in two US states – Washington and Colorado – approved ballot initiatives to establish legally regulated markets for the production, sale, use and taxation of cannabis (commonly referred to in the US as marijuana). This is the first time anywhere in the world that the recreational use of the drug will be legally regulated – the wellknown coffee shop system in the Netherlands is merely tolerated rather than enshrined in law. Needless to say, with implications both within and beyond US borders, the drug policy community is watching Colorado and Washington closely.
The Transnational Institute (TNI) organized an expert seminar on Costs and Benefits of Cannabis Regulation Models in Europe in Amsterdam, The Netherlands on October 31/November 1, 2013. The objective of the seminar was to identify and map existing and possible future cannabis regulation models in Europe, looking at the local, provincial and national levels and the potential impact of such models on the illicit cannabis market.